Celeste Warren said in a LinkedIn post that she is retiring from Merck on July 7. Warren joined Merck in 1997 and has been VP ...

Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting down its only factory, and shifting away ...

Fauna Bio, a biotech that mines data on disease resistance from squirrels and other animals to create new drugs, is looking ...

MoonLake Immunotherapeutics expects mid-year readout for Phase 3 trials of sonelokimab in hidradenitis suppurativa; CEO da ...

Pfizer's pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a ...

Endo to merge with Mallinckrodt in $6.7B deal. Combined revenue expected at $3.6B by 2025. Deal to close in H2 2025.

Montara Therapeutics has raised $20 million in an expanded seed financing to advance a pipeline of preclinical CNS candidates ...

Dave Weldon will not be the next director of the CDC, after the White House pulled his nomination just hours ahead of a ...

GoodRx’s brand new CEO, Wendy Barnes, says her job is not so much to fix anything, but to speed up the company’s current ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

Hinge Health files IPO with CEO Daniel Perez holding 19% voting power. Major clients include HCSC, Elevance Health & Aetna.

Mallinckrodt Pharmaceuticals and Endo are in talks over a potential merger worth about $7 billion, according to a report from ...